# Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

> **NCT00418951** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Voriconazole
- **DRUG:** Liposomal amphotericin B
- **DRUG:** Liposomal amphotericin B

## Key facts

- **NCT ID:** NCT00418951
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418951, "Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00418951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*